Occam Places Kevin Coveney as CFO of Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, has added Kevin Coveney to its executive ranks. Kevin brings to Enveric three decades of accounting, finance, and operations experience, having previously served as Chief Financial Officer for multiple biotechnology companies.
Previously, Kevin was CFO of Memgen, Inc., a clinical-stage immune-oncology company focused on developing immunotherapies that can safely activate the immune system and be combined with other drugs to eradicate cancer. Prior to Memgen, Kevin was CFO of Q-State Biosciences, a biotech focused on CNS disorders.
Earlier in his career, Coveney also held senior positions at several global accounting firms, including Deloitte & Touche and Ernst & Young. Coveney earned his BS in management from the University of Massachusetts and served as a non-commissioned officer in the United States Coast Guard.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.